earticle

논문검색

N-terminal Specific PEGylated TNF-Related N-terminal Specific PEGylated TNF-Related

초록

영어

Tumor necrosis factor(TNF)-related apoptosis-inducing ligand(TRAIL) is an attractive anticancer therapeutic due to the tumor cell specificity. However its rapid inactivation, low stability and solubility, and severe hepatotoxicity on systemic delivery have been considered as critical obstacles for clinical applications. Chemical PEGylation is a known means to increase stability and to influence pharmacokinetic properties of a protein therapeutic.
In this study, we applied the N-terminal specific PEGylation technology on active trimeric TRAIL for enhanced pharmaceutical characteristics with improved tumor therapeutic efficacy. The PEG-TRAIL showed improved physiological stability and pharmacokinetic profile than unmodified TRAIL with minimal activity loss. The improved pharmacological characteristics resulted in the
enhanced therapeutic potentials on inoculated tumor animal models without detectable side effects. Furthermore, the in vivo tumor targeting capacity might offer the possibility of the PEG-TRAIL as new tumor target therapeutics.

저자정보

  • Kang Choon Lee College of Pharmacy, SungKyunKwan University
  • Cheng-Hao Jin College of Pharmacy, SungKyunKwan University, Suwon 440-746
  • Su Young Chae College of Pharmacy, SungKyunKwan University, Suwon 440-746
  • Tae Hyung Kim College of Pharmacy, SungKyunKwan University, Suwon 440-746

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.